Clinical Trial Detail

NCT ID NCT04120246
Title Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Washington
Indications

Her2-receptor positive breast cancer

Therapies

alpha-TEA + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST